I think several people are beginning to realize the greater potential of the packaged vs bulk sales strategy by the company. These thinly traded stocks can soar quickly on good news and vice versa. Right now, the picture looks a bit brighter and, if management can leverage the borrowed money effectively, they should continue to progress. I guess a takeover is not out of the range of possibilities. I am holding right now but those with more of a risk appetite might dip their toes in the water.
About a year and a half ago, their branded share of the retail market for its two products was about 37%. Now it is 50%. As I've mentioned before, Our CEO came from Pharmavite, which had the number 1 brand in retail nutritional products (Nature Made) in the chain stores, and our CEO Bailey had been instrumental in bringing it to that retail position. And he's brought this great team from Pharmavite with him. That's why I believe that Director Davis bought a huge amount of shares (and hasn't sold) when Mr. Bailey came on board Cyanotech. I knew what a tough competitor Pharmavite had been, since I had been heavily invested in NBTY for years (itself a formidable competitor for shelf space) before it was bought out, and I jumped at the chance to buy heavily into CYAN. It's extremely difficult to gain and hold shelf space; It's so limited and the competition is absolutely ferocious. I can't emphasize that enough, so this company has this great advantage over its competitors. It will be so hard for new entrants into the Astaxanthin and Spirulina markets to knock Cyanotech off its retail perch once it gets firmly established, as it appears to be doing. I'm actually surprised, despite the small size of this company, that no analysts have looked closer at this story. Just as well: it has allowed us to buy this thing at dirt-cheap prices.